首页 > 最新文献

Revue neurologique最新文献

英文 中文
Ischemic stroke care for patients affiliated to the French agricultural health insurance scheme: A national study.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-22 DOI: 10.1016/j.neurol.2025.01.410
O Grimaud, S Kerbrat, L Menant, S Timsit, J-M André, E Nowak, V Olié, C Padilla, N Le Meur

Background: Health disparities along the rural-urban spectrum are a growing concern. The objective of this study was to determine whether in France, clinical profile, care and outcome after ischemic stroke differed between patients affiliated to the statutory health insurance system dedicated to the agricultural economic sector (i.e., Mutualité Sociale Agricole [MSA]) and all other patients.

Methods: Data on all patients aged≥20 years hospitalized for ischemic stroke in mainland France in 2018 were extracted from the French National Health Insurance Data System. Age-standardized percentages were used to compare the care accessed by MSA versus other stroke patients. Associations between health insurance scheme and case fatality were assessed using Poisson regression.

Results: Of 87,864 stroke cases 7928 (9%) were MSA patients. MSA patients were more often rural dwellers (75.4 versus 32%) and older (median age: 84 versus 76 years). In the 12 months prior to the stroke, access to general practitioner (GP) was similar, but MSA patients were less likely to have an appointment with a cardiologist. Pre-stroke drug prescriptions suggested a better cardiovascular profile in male MSA patients (e.g., antidiabetics: 18.1 versus 21.5%). A part from a lower access to stroke unit (e.g., women: 55.3 versus 59%) other acute care indicators, including reperfusion therapy, were comparable. The crude 7-day case fatality was higher for MSA patients (Relative Risk [RR]: 1.44, 95% CI [1.32-1.57]), but this disadvantage reduced to non-significant level after adjustment for age, comorbidities and stroke management (adjusted RR: 1.07 95% CI [0.98-1.18]) CONCLUSIONS: For the mostly farming, rural, MSA population, pre-stroke, acute and post-stroke care did not differ markedly from that provided to other patients. The lower density of GP in rural areas and the remoteness from specialized center did not result in less access to preventive and acute stroke care for MSA patients in 2018.

{"title":"Ischemic stroke care for patients affiliated to the French agricultural health insurance scheme: A national study.","authors":"O Grimaud, S Kerbrat, L Menant, S Timsit, J-M André, E Nowak, V Olié, C Padilla, N Le Meur","doi":"10.1016/j.neurol.2025.01.410","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.410","url":null,"abstract":"<p><strong>Background: </strong>Health disparities along the rural-urban spectrum are a growing concern. The objective of this study was to determine whether in France, clinical profile, care and outcome after ischemic stroke differed between patients affiliated to the statutory health insurance system dedicated to the agricultural economic sector (i.e., Mutualité Sociale Agricole [MSA]) and all other patients.</p><p><strong>Methods: </strong>Data on all patients aged≥20 years hospitalized for ischemic stroke in mainland France in 2018 were extracted from the French National Health Insurance Data System. Age-standardized percentages were used to compare the care accessed by MSA versus other stroke patients. Associations between health insurance scheme and case fatality were assessed using Poisson regression.</p><p><strong>Results: </strong>Of 87,864 stroke cases 7928 (9%) were MSA patients. MSA patients were more often rural dwellers (75.4 versus 32%) and older (median age: 84 versus 76 years). In the 12 months prior to the stroke, access to general practitioner (GP) was similar, but MSA patients were less likely to have an appointment with a cardiologist. Pre-stroke drug prescriptions suggested a better cardiovascular profile in male MSA patients (e.g., antidiabetics: 18.1 versus 21.5%). A part from a lower access to stroke unit (e.g., women: 55.3 versus 59%) other acute care indicators, including reperfusion therapy, were comparable. The crude 7-day case fatality was higher for MSA patients (Relative Risk [RR]: 1.44, 95% CI [1.32-1.57]), but this disadvantage reduced to non-significant level after adjustment for age, comorbidities and stroke management (adjusted RR: 1.07 95% CI [0.98-1.18]) CONCLUSIONS: For the mostly farming, rural, MSA population, pre-stroke, acute and post-stroke care did not differ markedly from that provided to other patients. The lower density of GP in rural areas and the remoteness from specialized center did not result in less access to preventive and acute stroke care for MSA patients in 2018.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The COVID-19 pandemic reduced delays in the care pathway for patients with glioma at a French institute.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-22 DOI: 10.1016/j.neurol.2025.01.412
M Brison, W Bouleftour, J-B Pelletier, F Vassal, F Barral-Clavel, E Jadaud, C Boutet, J-P Camdessanche, F Forest, C Ramirez

Context: Delays in cancer management have been reported during the COVID-19 pandemic. Neuro-oncology patients represent a real challenge as their disease can progress rapidly without appropriate care. However, data available for these patients over this period is scarce.

Objective: Therefore, the aim of this study was to examine the impact of the COVID-19 pandemic on therapeutic care within a specific population at a French institute. A retrospective descriptive study was conducted using electronic medical records. All patients who underwent surgery for glioma in a neurosurgery unit between January 1st, 2019 and December 31st, 2020 were included.

Results: A total of 114 patients were operated for a glioma; 70 patients in 2019 (before the pandemic) and 44 in 2020 (during the pandemic). Among these patients, 89% were diagnosed with a high-grade glioma, including 81% with glioblastoma. The mean time between first symptoms and imaging process increased from 35days in 2019 to 40days in 2020. However, in the subsequent steps of the care pathway, timelines improved at each stage with a reduction up to four days. The time reduction was statistically significant for two specific stages of care: (i) the interval between the surgery and the histomolecular diagnosis, with a reduction of two days, and (ii) the period between the histomoleculardiagnosis and the consultation for results announcement, with a reduction of three days. In summary, on average, the first treatment was initiated 49 days post-surgery in 2019 and 36days post-surgery in 2020.

Conclusion: This study showed that the COVID-19 outbreak positively impacted the therapeutic care pathway of patients with glioma at a French institute. Although the improvement can be measured in days, this acceleration of care was nonetheless crucial for the population studied.

{"title":"The COVID-19 pandemic reduced delays in the care pathway for patients with glioma at a French institute.","authors":"M Brison, W Bouleftour, J-B Pelletier, F Vassal, F Barral-Clavel, E Jadaud, C Boutet, J-P Camdessanche, F Forest, C Ramirez","doi":"10.1016/j.neurol.2025.01.412","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.412","url":null,"abstract":"<p><strong>Context: </strong>Delays in cancer management have been reported during the COVID-19 pandemic. Neuro-oncology patients represent a real challenge as their disease can progress rapidly without appropriate care. However, data available for these patients over this period is scarce.</p><p><strong>Objective: </strong>Therefore, the aim of this study was to examine the impact of the COVID-19 pandemic on therapeutic care within a specific population at a French institute. A retrospective descriptive study was conducted using electronic medical records. All patients who underwent surgery for glioma in a neurosurgery unit between January 1st, 2019 and December 31st, 2020 were included.</p><p><strong>Results: </strong>A total of 114 patients were operated for a glioma; 70 patients in 2019 (before the pandemic) and 44 in 2020 (during the pandemic). Among these patients, 89% were diagnosed with a high-grade glioma, including 81% with glioblastoma. The mean time between first symptoms and imaging process increased from 35days in 2019 to 40days in 2020. However, in the subsequent steps of the care pathway, timelines improved at each stage with a reduction up to four days. The time reduction was statistically significant for two specific stages of care: (i) the interval between the surgery and the histomolecular diagnosis, with a reduction of two days, and (ii) the period between the histomoleculardiagnosis and the consultation for results announcement, with a reduction of three days. In summary, on average, the first treatment was initiated 49 days post-surgery in 2019 and 36days post-surgery in 2020.</p><p><strong>Conclusion: </strong>This study showed that the COVID-19 outbreak positively impacted the therapeutic care pathway of patients with glioma at a French institute. Although the improvement can be measured in days, this acceleration of care was nonetheless crucial for the population studied.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinants of the experience of patients living with multiple sclerosis in terms of care pathway quality: An original French study.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-15 DOI: 10.1016/j.neurol.2025.01.375
D Veillard, K Baumstarck, A Ousmen, S Hamonic, G Edan, P Auquier

Purpose: Taking into account the experience of patients living with chronic diseases, like multiple sclerosis (MS), in the assessment of the quality of their care pathway contributes significantly to improve these quality and their own state of health. This challenge requires better identification of the determinants of this experience. The study aimed to explore the determinants of the experience of MS patients in France concerning their care pathway quality.

Patient and methods: This study was based on a dedicated cross-sectional national survey that took place in 2021. Teams from regional MS networks and MS unit at the hospital, as well as patients' associations, invited patients to participate throughout France. Patients' experience was assessed using the Musicare questionnaire. The determinants explored concerned their sociodemographic characteristics, quality of life and disease characteristics. To explore association between MusiCare questionnaire dimension scores and these determinants, bivariate and multivariate analysis were performed.

Results: Data were exploitable for 1971 patients living throughout France. Multivariate analysis identified significant relationships between all but one of the Musicare dimensions and several of the determinants considered in this study. The presence of a supportive caregiver, better quality of life scores, receiving specialized follow-up for MS, being a male patient and long-term illness significantly improves patient experience on one or more dimensions of the Musicare questionnaire.

Conclusion: Some of these results are consistent with those of previous studies on other chronic diseases. They require confirmation, but they pave the way for targeted interventions for these patients in France.

{"title":"Determinants of the experience of patients living with multiple sclerosis in terms of care pathway quality: An original French study.","authors":"D Veillard, K Baumstarck, A Ousmen, S Hamonic, G Edan, P Auquier","doi":"10.1016/j.neurol.2025.01.375","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.375","url":null,"abstract":"<p><strong>Purpose: </strong>Taking into account the experience of patients living with chronic diseases, like multiple sclerosis (MS), in the assessment of the quality of their care pathway contributes significantly to improve these quality and their own state of health. This challenge requires better identification of the determinants of this experience. The study aimed to explore the determinants of the experience of MS patients in France concerning their care pathway quality.</p><p><strong>Patient and methods: </strong>This study was based on a dedicated cross-sectional national survey that took place in 2021. Teams from regional MS networks and MS unit at the hospital, as well as patients' associations, invited patients to participate throughout France. Patients' experience was assessed using the Musicare questionnaire. The determinants explored concerned their sociodemographic characteristics, quality of life and disease characteristics. To explore association between MusiCare questionnaire dimension scores and these determinants, bivariate and multivariate analysis were performed.</p><p><strong>Results: </strong>Data were exploitable for 1971 patients living throughout France. Multivariate analysis identified significant relationships between all but one of the Musicare dimensions and several of the determinants considered in this study. The presence of a supportive caregiver, better quality of life scores, receiving specialized follow-up for MS, being a male patient and long-term illness significantly improves patient experience on one or more dimensions of the Musicare questionnaire.</p><p><strong>Conclusion: </strong>Some of these results are consistent with those of previous studies on other chronic diseases. They require confirmation, but they pave the way for targeted interventions for these patients in France.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trigeminal autonomic cephalalgia after common eye surgery: Case series and literature review.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-10 DOI: 10.1016/j.neurol.2025.01.305
M Beltramone, S Redon, A Donnet

Background: Secondary cases of trigeminal autonomic cephalalgia have been described, most commonly following tumor, trauma, or vascular causes.

Cases: We report a series of 6 patients who experienced ipsilateral headache responding to the International Headache Society criteria for cluster headache, hemicrania continua or probable hemicrania continua. It occurred immediately or in the following days or weeks after cataract or glaucoma surgery. We complete these descriptions with 4 cases from a literature review of trigeminal autonomic cephalalgia attributed to non-destructive eye surgery.

Conclusion: We report the largest series of patients who developed TAC after ocular surgery, supplemented by 4 cases from the literature. For many of these patients, TAC treatments can be effective either as a preventive or as an attack.

{"title":"Trigeminal autonomic cephalalgia after common eye surgery: Case series and literature review.","authors":"M Beltramone, S Redon, A Donnet","doi":"10.1016/j.neurol.2025.01.305","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.305","url":null,"abstract":"<p><strong>Background: </strong>Secondary cases of trigeminal autonomic cephalalgia have been described, most commonly following tumor, trauma, or vascular causes.</p><p><strong>Cases: </strong>We report a series of 6 patients who experienced ipsilateral headache responding to the International Headache Society criteria for cluster headache, hemicrania continua or probable hemicrania continua. It occurred immediately or in the following days or weeks after cataract or glaucoma surgery. We complete these descriptions with 4 cases from a literature review of trigeminal autonomic cephalalgia attributed to non-destructive eye surgery.</p><p><strong>Conclusion: </strong>We report the largest series of patients who developed TAC after ocular surgery, supplemented by 4 cases from the literature. For many of these patients, TAC treatments can be effective either as a preventive or as an attack.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective, descriptive study of acute myelitis in French Guyana.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-31 DOI: 10.1016/j.neurol.2025.01.002
P Grimont, A Montcuquet, F Quet, B De Toffol, N Deschamps

Background: Acute myelitis is a neurological entity, often posing the problem of etiology. The two main causes are infectious or autoimmune. French Guyana is a region of the world where infectious etiologies are multiple, in particular human immunodeficiency virus infection, and autoimmune diseases appear to be emerging. The aim of our study was firstly to determine the proportion of each etiology of acute myelitis in French Guyana, and secondly to describe the clinical, paraclinical and epidemiological characteristics of autoimmune myelitis in French Guyana, with particular reference to neuromyelitis optica spectrum disorder (NMOSD).

Methods: This retrospective, observational study included all patients who presented with acute myelitis between January 2015 and August 2023 at Cayenne Hospital Center. Each patient's chart was reviewed and patients were classified according to etiology. Demographic and clinical data were collected, as well as blood, lumbar puncture, and cerebral and spinal cord magnetic resonance imaging results.

Results: Of the 40 patients included, immune etiology was found in 74%, including 49% with NMOSD (37% with positive anti-aquaporin-4 antibodies) compared with three patients with infectious etiology. There was no statistically significant difference in complementary examinations between immune and infectious etiologies. The prevalence of NMOSD in French Guyana was estimated at 8/100,000 (6/100,000 for patients with positive anti-aquaporin-4 antibodies). No significant difference in the geographic distribution of patients with NMOSD in French Guyana was demonstrated.

Conclusions: Our results show a high proportion of autoimmune etiology of acute myelitis in French Guyana, and more particularly of NMOSD. There is a high prevalence of NMOSD, the second highest in the world after the French West Indies. Given this high proportion of autoimmune myelitis, several hypotheses can be put forward, with genetic and environmental factors in the foreground. For patients with acute myelitis in French Guyana, an immune cause is the most likely. It is therefore important to think about this and look for NMOSD in particular, without ignoring an infectious etiology.

{"title":"Retrospective, descriptive study of acute myelitis in French Guyana.","authors":"P Grimont, A Montcuquet, F Quet, B De Toffol, N Deschamps","doi":"10.1016/j.neurol.2025.01.002","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.002","url":null,"abstract":"<p><strong>Background: </strong>Acute myelitis is a neurological entity, often posing the problem of etiology. The two main causes are infectious or autoimmune. French Guyana is a region of the world where infectious etiologies are multiple, in particular human immunodeficiency virus infection, and autoimmune diseases appear to be emerging. The aim of our study was firstly to determine the proportion of each etiology of acute myelitis in French Guyana, and secondly to describe the clinical, paraclinical and epidemiological characteristics of autoimmune myelitis in French Guyana, with particular reference to neuromyelitis optica spectrum disorder (NMOSD).</p><p><strong>Methods: </strong>This retrospective, observational study included all patients who presented with acute myelitis between January 2015 and August 2023 at Cayenne Hospital Center. Each patient's chart was reviewed and patients were classified according to etiology. Demographic and clinical data were collected, as well as blood, lumbar puncture, and cerebral and spinal cord magnetic resonance imaging results.</p><p><strong>Results: </strong>Of the 40 patients included, immune etiology was found in 74%, including 49% with NMOSD (37% with positive anti-aquaporin-4 antibodies) compared with three patients with infectious etiology. There was no statistically significant difference in complementary examinations between immune and infectious etiologies. The prevalence of NMOSD in French Guyana was estimated at 8/100,000 (6/100,000 for patients with positive anti-aquaporin-4 antibodies). No significant difference in the geographic distribution of patients with NMOSD in French Guyana was demonstrated.</p><p><strong>Conclusions: </strong>Our results show a high proportion of autoimmune etiology of acute myelitis in French Guyana, and more particularly of NMOSD. There is a high prevalence of NMOSD, the second highest in the world after the French West Indies. Given this high proportion of autoimmune myelitis, several hypotheses can be put forward, with genetic and environmental factors in the foreground. For patients with acute myelitis in French Guyana, an immune cause is the most likely. It is therefore important to think about this and look for NMOSD in particular, without ignoring an infectious etiology.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ureaplasma urealyticum septic hip arthritis associated with ocrelizumab therapy in a young patient with multiple sclerosis.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-27 DOI: 10.1016/j.neurol.2025.01.003
J Le Bars, L Picard, M Hervouet, E Le Page
{"title":"Ureaplasma urealyticum septic hip arthritis associated with ocrelizumab therapy in a young patient with multiple sclerosis.","authors":"J Le Bars, L Picard, M Hervouet, E Le Page","doi":"10.1016/j.neurol.2025.01.003","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.003","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke Triage Alpha Rescue Score (STARS): Prehospital phone-based tool to identify cerebral large vessel occlusion.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-27 DOI: 10.1016/j.neurol.2025.01.004
P Morin, A Boissieux, V Brenckmann, H Merlin, A Baquerre, S Marcel, O Detante, P Usseglio, G Debaty, I Favre-Wiki, J Papassin

Introduction: Prehospital identification of stroke patients with large vessel occlusion (LVO) is crucial to optimize transport to an endovascular thrombectomy (EVT)-capable center. Existing scores require medical or paramedical expertise and specific teachings. We aimed to validate a simple prehospital phone-based score for LVO identification.

Methods: First, the Stroke Triage Alpha Rescue Score (STARS) was designed among a retrospective cohort of 3452 stroke alerts from the Emergency Medical Dispatch Centers (EMDC) registry. Phone-based neurological assessment, characteristics, final diagnosis, and brain imaging were analyzed. The items weighting was based on odds ratios (ORs) of significant variables after multivariate analysis. Secondly, STARS was assessed by dispatchers for all suspected strokes in a prospective cohort. Receiver operating curve (ROC) and predictive performances were calculated for the external validation.

Results: In the retrospective cohort, the best balance between specificity and sensitivity was obtained with a combination of six items (presence or absence of: upper, lower limbs motor deficits, language impairment, facial palsy, consciousness disorder, smoking). Each item value was determined according to their respective OR to obtain a total STARS between 0 and 13, with the most favorable cut-off higher or equal to 7 points. Then, STARS was prospectively assessed in 799 stroke alerts between March 2021 and March 2022. LVO was finally detected in 63 of 653 patients (9.6%). The area under the ROC was 0.83 [95% CI: 0.78; 0.88]. STARS≥7 had 0.83 accuracy, 0.65 sensitivity, and 0.85 specificity for detecting LVO.

Conclusion: STARS is a simple and accurate phone-based score, without specific teaching, to detect LVO in prehospital network. STARS correctly classified 83% of stroke alerts and could be useful to identify patients with LVO eligible for EVT.

{"title":"Stroke Triage Alpha Rescue Score (STARS): Prehospital phone-based tool to identify cerebral large vessel occlusion.","authors":"P Morin, A Boissieux, V Brenckmann, H Merlin, A Baquerre, S Marcel, O Detante, P Usseglio, G Debaty, I Favre-Wiki, J Papassin","doi":"10.1016/j.neurol.2025.01.004","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.004","url":null,"abstract":"<p><strong>Introduction: </strong>Prehospital identification of stroke patients with large vessel occlusion (LVO) is crucial to optimize transport to an endovascular thrombectomy (EVT)-capable center. Existing scores require medical or paramedical expertise and specific teachings. We aimed to validate a simple prehospital phone-based score for LVO identification.</p><p><strong>Methods: </strong>First, the Stroke Triage Alpha Rescue Score (STARS) was designed among a retrospective cohort of 3452 stroke alerts from the Emergency Medical Dispatch Centers (EMDC) registry. Phone-based neurological assessment, characteristics, final diagnosis, and brain imaging were analyzed. The items weighting was based on odds ratios (ORs) of significant variables after multivariate analysis. Secondly, STARS was assessed by dispatchers for all suspected strokes in a prospective cohort. Receiver operating curve (ROC) and predictive performances were calculated for the external validation.</p><p><strong>Results: </strong>In the retrospective cohort, the best balance between specificity and sensitivity was obtained with a combination of six items (presence or absence of: upper, lower limbs motor deficits, language impairment, facial palsy, consciousness disorder, smoking). Each item value was determined according to their respective OR to obtain a total STARS between 0 and 13, with the most favorable cut-off higher or equal to 7 points. Then, STARS was prospectively assessed in 799 stroke alerts between March 2021 and March 2022. LVO was finally detected in 63 of 653 patients (9.6%). The area under the ROC was 0.83 [95% CI: 0.78; 0.88]. STARS≥7 had 0.83 accuracy, 0.65 sensitivity, and 0.85 specificity for detecting LVO.</p><p><strong>Conclusion: </strong>STARS is a simple and accurate phone-based score, without specific teaching, to detect LVO in prehospital network. STARS correctly classified 83% of stroke alerts and could be useful to identify patients with LVO eligible for EVT.</p>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of subarachnoid haemorrhage: It is time to use spectrophotometry.
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-21 DOI: 10.1016/j.neurol.2025.01.001
X Moisset, G Demarquay, D Bouvier
{"title":"Diagnosis of subarachnoid haemorrhage: It is time to use spectrophotometry.","authors":"X Moisset, G Demarquay, D Bouvier","doi":"10.1016/j.neurol.2025.01.001","DOIUrl":"https://doi.org/10.1016/j.neurol.2025.01.001","url":null,"abstract":"","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of optic disc edema in 2021/2022: Results from a cohort of 197 patients 2021/2022 年视盘水肿的流行病学:197 例患者的研究结果。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-01 DOI: 10.1016/j.neurol.2024.09.010
R. Attia , N. Stolowy , R. Fitoussi , K. Mairot , T. David

Objective

The aim of our study was to determine the etiologies of optic disc edema between 2021 and 2022.

Materials and methods

This was a multicentric study at the Timone and Nord university hospitals in Marseille. Patients were retrospectively followed in ophthalmology departments, with inclusion between January 2021 and December 2022. All patients presenting with newly diagnosed uni- or bilateral optic disc edema, both adults and children, were included. Their ophthalmological evaluation included a fundus examination and optical coherence tomography if feasible.

Results

In total, 197 patients were included. Intracranial hypertension (IH) was the most frequent etiology (37.06%). The primary causes of IH were idiopathic (27/73), intracranial tumors (21/73), and cerebral venous thrombosis (12/73). The second etiology of optic disc edema was retinal vein occlusion in 19.9% of cases (39/197). Edema reactive to uveitis was found in 13.2% of cases (26/197). Finally, inflammatory (17/197) and ischemic (30/197) optic neuropathies were identified.

Conclusion

This study updates the most frequent etiologies of optic disc edema in 2021 and 2022 to facilitate diagnostic hypotheses for de novo optic disc edema. It highlights the importance of a comprehensive and personalized evaluation in diagnosing optic disc edema, taking into account recent advances in imaging techniques and biomarkers.
研究目的我们的研究旨在确定 2021 年至 2022 年间视盘水肿的病因:这是在马赛的蒂莫内和诺德大学医院进行的一项多中心研究。眼科部门对患者进行了回顾性随访,纳入时间为 2021 年 1 月至 2022 年 12 月。所有新确诊的单侧或双侧视盘水肿患者(包括成人和儿童)均被纳入研究范围。眼科评估包括眼底检查和光学相干断层扫描(如可行):结果:共纳入 197 名患者。颅内高压(IH)是最常见的病因(37.06%)。IH的主要病因是特发性(27/73)、颅内肿瘤(21/73)和脑静脉血栓(12/73)。视盘水肿的第二个病因是视网膜静脉闭塞,占 19.9%(39/197)。葡萄膜炎反应性水肿占 13.2%(26/197)。最后,还发现了炎症性(17/197)和缺血性(30/197)视神经病变:本研究更新了 2021 年和 2022 年最常见的视盘水肿病因,有助于对新发视盘水肿提出诊断假设。它强调了结合成像技术和生物标志物的最新进展,在诊断视盘水肿时进行全面和个性化评估的重要性。
{"title":"Epidemiology of optic disc edema in 2021/2022: Results from a cohort of 197 patients","authors":"R. Attia ,&nbsp;N. Stolowy ,&nbsp;R. Fitoussi ,&nbsp;K. Mairot ,&nbsp;T. David","doi":"10.1016/j.neurol.2024.09.010","DOIUrl":"10.1016/j.neurol.2024.09.010","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of our study was to determine the etiologies of optic disc edema between 2021 and 2022.</div></div><div><h3>Materials and methods</h3><div>This was a multicentric study at the Timone and Nord university hospitals in Marseille. Patients were retrospectively followed in ophthalmology departments, with inclusion between January 2021 and December 2022. All patients presenting with newly diagnosed uni- or bilateral optic disc edema, both adults and children, were included. Their ophthalmological evaluation included a fundus examination and optical coherence tomography if feasible.</div></div><div><h3>Results</h3><div>In total, 197 patients were included. Intracranial hypertension (IH) was the most frequent etiology (37.06%). The primary causes of IH were idiopathic (27/73), intracranial tumors (21/73), and cerebral venous thrombosis (12/73). The second etiology of optic disc edema was retinal vein occlusion in 19.9% of cases (39/197). Edema reactive to uveitis was found in 13.2% of cases (26/197). Finally, inflammatory (17/197) and ischemic (30/197) optic neuropathies were identified.</div></div><div><h3>Conclusion</h3><div>This study updates the most frequent etiologies of optic disc edema in 2021 and 2022 to facilitate diagnostic hypotheses for de novo optic disc edema. It highlights the importance of a comprehensive and personalized evaluation in diagnosing optic disc edema, taking into account recent advances in imaging techniques and biomarkers.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"181 1","pages":"Pages 93-97"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adding corticosteroids to galcanezumab in medication overuse headache: A three-arm head-to-head prospective observational cohort study 在治疗药物滥用性头痛时,在加坎儿珠单抗中加入皮质类固醇:三臂头对头前瞻性观察队列研究。
IF 2.8 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-01-01 DOI: 10.1016/j.neurol.2024.10.003
S. Braca, R. De Simone, A. Stornaiuolo, G. Cretella, A. Miele, C.V. Russo

Background

Medication overuse headache (MOH) is a condition where pain relief medications cause chronic headaches due to excessive use. Recent advancements highlight the effectiveness of preventive treatments like anti-CGRP monoclonal antibodies. Current strategies combine medication withdrawal and preventive treatments, with corticosteroids traditionally used to ease withdrawal symptoms.

Methods

This is a prospective three-arm observational cohort study comparing the effectiveness and safety of galcanezumab alone, galcanezumab plus prednisone and prednisone alone for the treatment of MOH. We enrolled 75 patients. Prednisone was administered at an initial dose of 50 mg daily, and then tapered off over 28 days. Duration of follow-up was 3 months.

Results

All treatments proved effective (P < 0.001). We found a significant reduction of mean monthly days with headache in the galcanezumab plus prednisone group (baseline: 25, IQR: 20–30; after 3 months: 7, IQR: 5–10), in the galcanezumab group (baseline: 25, IQR: 20–30; after 3 months: 10, IQR: 5–14) and in the Prednisone group (baseline: 25, IQR: 20–28; after 3 months: median: 15 days, IQR: 8–22 days). Patients treated with prednisone reported a higher incidence of side effects (P = 0.002).

Conclusion

Our study indicates that both galcanezumab and prednisone decrease the frequency of headaches in patients with MOH. The combined usage of these treatments showed the highest reduction in mean monthly headache days. However, treatment with prednisone determined a significant rate of adverse events, therefore we suggest its use only in unresponsive patients. In all other patients galcanezumab appears to be a safe and effective option.
背景:药物过度使用性头痛(MOH)是一种因过度使用止痛药物而导致慢性头痛的病症。最近的研究进展突显了抗 CGRP 单克隆抗体等预防性治疗的有效性。目前的策略是将停药和预防性治疗结合起来,传统上使用皮质类固醇来缓解停药症状:这是一项前瞻性三臂观察性队列研究,比较了单用加奈珠单抗、加奈珠单抗加泼尼松和单用泼尼松治疗MOH的有效性和安全性。我们共招募了75名患者。泼尼松的初始剂量为每天50毫克,然后在28天内逐渐减量。随访时间为 3 个月:结果:所有治疗方法均有效(PC结论:所有治疗方法均有效:我们的研究表明,加康珠单抗和泼尼松都能降低MOH患者的头痛频率。联合使用这两种疗法后,每月平均头痛天数的减少幅度最大。然而,使用泼尼松治疗会产生大量不良反应,因此我们建议仅在无反应的患者中使用。对于所有其他患者,加康珠单抗似乎是一种安全有效的选择。
{"title":"Adding corticosteroids to galcanezumab in medication overuse headache: A three-arm head-to-head prospective observational cohort study","authors":"S. Braca,&nbsp;R. De Simone,&nbsp;A. Stornaiuolo,&nbsp;G. Cretella,&nbsp;A. Miele,&nbsp;C.V. Russo","doi":"10.1016/j.neurol.2024.10.003","DOIUrl":"10.1016/j.neurol.2024.10.003","url":null,"abstract":"<div><h3>Background</h3><div>Medication overuse headache (MOH) is a condition where pain relief medications cause chronic headaches due to excessive use. Recent advancements highlight the effectiveness of preventive treatments like anti-CGRP monoclonal antibodies. Current strategies combine medication withdrawal and preventive treatments, with corticosteroids traditionally used to ease withdrawal symptoms.</div></div><div><h3>Methods</h3><div>This is a prospective three-arm observational cohort study comparing the effectiveness and safety of galcanezumab alone, galcanezumab plus prednisone and prednisone alone for the treatment of MOH. We enrolled 75 patients. Prednisone was administered at an initial dose of 50<!--> <!-->mg daily, and then tapered off over 28<!--> <!-->days. Duration of follow-up was 3<!--> <!-->months.</div></div><div><h3>Results</h3><div>All treatments proved effective (<em>P</em> <!-->&lt;<!--> <!-->0.001). We found a significant reduction of mean monthly days with headache in the galcanezumab plus prednisone group (baseline: 25, IQR: 20–30; after 3<!--> <!-->months: 7, IQR: 5–10), in the galcanezumab group (baseline: 25, IQR: 20–30; after 3<!--> <!-->months: 10, IQR: 5–14) and in the Prednisone group (baseline: 25, IQR: 20–28; after 3<!--> <!-->months: median: 15 days, IQR: 8–22<!--> <!-->days). Patients treated with prednisone reported a higher incidence of side effects (<em>P</em> <!-->=<!--> <!-->0.002).</div></div><div><h3>Conclusion</h3><div>Our study indicates that both galcanezumab and prednisone decrease the frequency of headaches in patients with MOH. The combined usage of these treatments showed the highest reduction in mean monthly headache days. However, treatment with prednisone determined a significant rate of adverse events, therefore we suggest its use only in unresponsive patients. In all other patients galcanezumab appears to be a safe and effective option.</div></div>","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":"181 1","pages":"Pages 106-113"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revue neurologique
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1